NRSN — NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ
- Employees: 17
- Website: https://www.neurosense-tx.com
Latest SEC filings for NRSN
- 6-K — 2026-08-27
- 6-K — 2026-03-24
- 6-K — 2026-02-13
- F-3 — 2026-01-29
- 6-K — 2026-01-06
- 6-K — 2025-12-22
- 6-K — 2025-12-08
- 6-K — 2025-12-04
- 424B3 — 2025-11-26
- 6-K — 2025-11-24
Latest NRSN news
- — NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones (prnewswire.com)
- — NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference (prnewswire.com)
- — NeuroSense Therapeutics GAAP EPS of -$2.10 beats by $1.83 (seekingalpha_market)
- — NeuroSense Provides Business Update and Progress for the First Half of 2026 (prnewswire.com)
Educational tool only — not investment advice.